Millions still lack access to life-saving medicines, not because science failed, but because patents, prices, and politics get in the way. This deep dive unpacks how countries have used (and sometimes avoided) TRIPS flexibilities over the past 25 years to break monopolies, enable generics, and respond to crises from HIV to COVID-19 and cancer. With ...







